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Alzheimer, Parkinson and other neurodegenerative diseases involve a series of
brain proteins, referred to as ‘amyloidogenic proteins’, with exceptional
conformational plasticity and a high propensity for self-aggregation. Although
the mechanisms by which amyloidogenic proteins kill neural cells are not fully
understood, a common feature is the concentration of unstructured
amyloidogenic monomers on bidimensional membrane lattices. Membrane-
bound monomers undergo a series of lipid-dependent conformational
changes, leading to the formation of oligomers of varying toxicity rich in
β-sheet structures (annular pores, amyloid fibrils) or in α-helix structures
(transmembrane channels). Condensed membrane nano- or microdomains
formed by sphingolipids and cholesterol are privileged sites for the binding
and oligomerisation of amyloidogenic proteins. By controlling the balance
between unstructured monomers and α or β conformers (the chaperone
effect), sphingolipids can either inhibit or stimulate the oligomerisation of
amyloidogenic proteins. Cholesterol has a dual role: regulation of
protein–sphingolipid interactions through a fine tuning of sphingolipid
conformation (indirect effect), and facilitation of pore (or channel) formation
through direct binding to amyloidogenic proteins. Deciphering this complex
network of molecular interactions in the context of age- and disease-related
evolution of brain lipid expression will help understanding of how
amyloidogenic proteins induce neural toxicity and will stimulate the
development of innovative therapies for neurodegenerative diseases.
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sThe discovery that a significant proportion of
cellular proteins do not have a well-defined
structure under physiological conditions is one
of the most fascinating concepts in modern
biology (Ref. 1). This iconoclastic finding has
shaken the broadly accepted dogma that a
protein is predisposed to fold into a unique
structure that is specified by its amino acid
sequence.
Proteins that lack a well-defined 3D structure
have been referred to as ‘intrinsically disordered
proteins’ (IDPs), and they constitute the part of
the proteome called the ‘unfoldome’ (Ref. 2).
IDPs perform a wide range of regulatory
functions related to signal transduction,
molecular recognition and molecular assembly
(Ref. 3), and several have been implicated in
fatal human pathologies (Ref. 4). One
representative member of IDPs is α-synuclein
(encoded by SNCA), a brain protein associated
with Parkinson disease. Depending on its
environment, α-synuclein can adopt a variety of
structurally unrelated conformations (Fig. 1),
from a natively unfolded (mostly disordered)
state to different α-helical or β-structural species
folded to a different degree (Ref. 5). The protein
can also self-aggregate and form various types
of supramolecular assemblies with different
morphology, including oligomers, amorphous
aggregates and amyloid-like fibrils (Ref. 5). This
incredible level of conformational plasticity is
also a hallmark of other amyloidogenic proteins,
such as amyloid β (Aβ; encoded by APP)
involved in Alzheimer disease and the prion
protein (PrP; encoded by PRNP) involved in
Creutzfeldt–Jakob disease and prion infections
(Ref. 6). Some amyloidogenic proteins
(Alzheimer Aβ peptides, α-synuclein) belong to
the IDP family; in other cases (e.g. PrP), the
protein has a 3D structure but can misfold into
an alternative structure that is prone to
aggregation. There are several mechanisms by
which an amyloidogenic protein can acquire a
disease-related 3D structure: overexpression,
mutations or other genetic alterations, and
exposure to harmful environmental conditions
(Ref. 2). These mechanisms have been
extensively studied during the past two decades.
However, how amyloidogenic proteins induce
cell death in these neurodegenerative diseases is
still a mystery. Given the high prevalence and
the fatal outcome of these pathologies in
humans, this is clearly one of the most
important challenges of biomedical research for
the 21st century.
Among the different research strategies in this
field, those aiming at identifying common
features in distinct amyloidogenic proteins have
been particularly fruitful. Obviously, it is
somewhat paradoxical that the similar
behaviour of amyloidogenic proteins – that is,
their conformational plasticity and aggregation
properties – does not rely on any kind of
homology in their amino acid sequence. Instead,
these common features might involve the 3D
structures of these proteins. A major
breakthrough was the identification of a
common epitope in oligomers formed by
various amyloidogenic proteins (Ref. 7). This
discovery suggested a universal mode of
oligomerisation underlying a common
mechanism of toxicity. Moreover, conformation-
dependent antibodies that recognise generic
epitopes have been used as a structural basis to
distinguish amyloid prefibrillar and fibrillar
oligomers (Ref. 8). A second breakthrough was
the demonstration that amyloidogenic proteins
can assemble into annular structures forming
amyloid pores with ion channel properties
(Refs 9, 10) (Fig. 1). This finding suggested that
amyloid oligomers could perturb membrane
permeability (e.g. cellular calcium fluxes) and
thus kill neuronal cells more efficiently than
amyloid fibrils. This mechanism, originally
proposed by Arispe et al. (Refs 11, 12) for
explaining the toxicity of Aβ, is now commonly
referred to as the β-amyloid calcium channel
hypothesis (Ref. 13). However, despite their
fruitful contribution to the field, these important
discoveries did not really inform us on the
molecular mechanisms involved in the different
modes of amyloid oligomerisation and
aggregation. To progress towards this
knowledge, we have to consider another
common feature tightly linked to the biology of
amyloids in the brain, which lies in their
immediate environment – that is, biological
membranes (Refs 13, 14). Indeed, Aβ peptides
are generated by the proteolytic cleavage of
a transmembrane precursor (the amyloid
protein precursor, APP) (Ref. 15), PrP is a
membrane protein anchored in the external
leaflet of the plasma membrane by a
glycosylphosphatidylinositol anchor (Ref. 16),
and α-synuclein is involved in the traffic of
synaptic vesicles (Ref. 17).
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sAmyloidogenic proteins reside in a lipid
world constituted by a myriad of lipid-based
structures such as internal membrane networks,
plasma membrane nano- and microdomains,
lipoproteins and exosomes. This is not totally
surprising if one considers that lipids are the
most abundant organic compounds found in the
brain, accounting for up to 50% of its dry
weight (Ref. 18). As in other mammalian tissues,
brain lipids consist of three major categories
in roughly equimolar proportions (Ref. 19):
glycerophospholipids, sphingolipids and
cholesterol. Sphingolipids and cholesterol self-
aggregate into specific membrane domains
referred to as nanodomains, microdomains,
caveolae, lipid shells or lipid rafts (Refs 20,
21). These sphingolipid–cholesterol-enriched
domains (the so-called lipid rafts) are in a
liquid-ordered (Lo) phase floating in the more
liquid glycerophospholipid-rich and cholesterol-
poor bulk (Ld phase) of the plasma membrane.
Lipid rafts are chiefly involved in cellular
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Different pathways of amyloidogenic protein oligomerisation and fibrillation on 
membrane surfaces
Expert Reviews in Molecular Medicine © Cambridge University Press 2010
Figure 1. Different pathways of amyloidogenic protein oligomerisation and fibrillation on membrane
surfaces. Upon interaction with neuronal membranes, unstructured soluble monomers of amyloidogenic
proteins undergo an α-helix shift of their conformation (a). Further accumulation of the proteins on the
surface of the membrane induces oligomerisation into β-sheet aggregates (b) or α-oligomers (c). Oligomers
with a β-sheet structure can form protofibrils (d), amyloid fibrils (e) and amyloid pores (annular protofibrils)
with ion-channel properties (f). In some instances (e.g. for α-synuclein), transmembrane channels can also
be generated by oligomers with an α-helix structure (g). In all cases, the formation of functional ion
channels requires the insertion and assembly of the oligomers in the neuronal membrane (green lipid
bilayer). Note the possibility of conversion between α- and β-oligomers (h).
expert reviews
http://www.expertreviews.org/ in molecular medicine
3
Accession information: doi:10.1017/S1462399410001602; Vol. 12; e27; September 2010
©Cambridge University Press 2010. Re-use permitted under a Creative Commons Licence – by-nc-sa.
M
o
l
e
c
u
l
a
r
i
n
s
i
g
h
t
s
i
n
t
o
a
m
y
l
o
i
d
r
e
g
u
l
a
t
i
o
n
b
y
m
e
m
b
r
a
n
e
c
h
o
l
e
s
t
e
r
o
l
a
n
d
s
p
h
i
n
g
o
l
i
p
i
d
s
:
c
o
m
m
o
n
m
e
c
h
a
n
i
s
m
s
i
n
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
strafficking and signalling functions (Ref. 22) and
are also preferential sites for host interactions
with pathogens and toxins (Ref. 23).
Theaimofthisreviewistoemphasisethespecific
role of cholesterol and sphingolipids, alone and in
combination, in the interaction between
amyloidogenic proteins and neural membranes,
and to figure out how these interactions can
affect the structural and functional properties of
these proteins. We also discuss the impact of age-
and disease-related changes in brain lipid content
on the pathophysiology of amyloid-associated
neurodegenerative diseases. We do not intend to
present a separate section for each amyloidogenic
protein (Aβ, α-synuclein, PrP, etc.). Instead, it is
our goal to identify common membrane-based
mechanisms that, at least at the molecular level,
might apply to any type of amyloidogenic
protein and thus could serve as a solid
biochemical background for studying amyloid
toxicity in the brain.
Mechanisms of concentration of
amyloidogenic proteins on neuronal
membranes
Reduction of dimensionality
There are two main mechanisms ensuring the
efficient transfer of amyloidogenic proteins from
the cytosolic or extracellular milieu to neuronal
plasma membranes. The first one is the
reduction of dimensionality (from 3D to 2D)
that occurs when a soluble protein dissolved in
the bulk solvent binds to a membrane surface
(Ref. 24). The underlying idea is that the
membrane 2D space can concentrate proteins far
more efficiently than the 3D space of the bulk
solvent. As a consequence, the average distance
between two proteins is shorter in 2D than in
3D, and this effect is more pronounced for
higher protein concentrations (Ref. 25). This
means that increased concentration of a protein
lowers the average protein–protein distance
more efficiently on a 2D surface than in a
3D space. Consequently, protein–protein
interactions are favoured in the 2D space. This
phenomenon is particularly important for
amyloidogenic proteins that tend to self-
aggregate after a conformational transition
(Fig. 2). Thus, the simple fact of the
concentration of monomers in a restricted
membrane area is, by itself, a crucial step in the
complex process of amyloid oligomerisation/
aggregation.
Specific binding to membrane lipids
The second mechanism explaining the affinity of
amyloidogenic proteins for neuronal membranes
is lipid specificity. Converging data obtained
from various laboratories with a broad range of
experimental approaches have shown that
amyloidogenic proteins interact with the lipids
found in the Lo phase – that is, sphingolipids
and cholesterol (Fig. 2). Alzheimer Aβ peptides
recognise several glycosphingolipids, including
neutral species such as asialo-GM1 or
galactosylceramide (GalCer) as well as gangliosides
such as GM1 (Refs 26, 27, 28, 29); α-synuclein
binds to gangliosides GM1 and GM3 (Refs 30,
31); PrP interacts with sphingomyelin, GalCer,
GM1 and GM3 (Refs 27, 32, 33) and is
associated with sphingolipid signalling
platforms (Ref. 34). Overall, this high affinity for
sphingolipids determines the concentration of
amyloid proteins in lipid raft areas of the
extracellular leaflet of the plasma membrane.
Several amyloidogenic proteins can also bind
to negatively charged glycerophospholipids
(Refs 35, 36), which are enriched in the
cytoplasmic leaflet of the plasma membrane
(Ref. 19). This type of interaction has been
extensively studied for α-synuclein, which
recognises anionic phosphatidylserine and
phosphatidylglycerol (Refs 36, 37, 38, 39). In this
review, we restrict our analysis to the role of
cholesterol and sphingolipids in the interaction
of amyloidogenic proteins and membranes. As
we will see, these lipids play a more active role
in the conformation, oligomerisation and
aggregation of amyloidogenic proteins than just
acting as a concentration platform.
Molecular mechanisms of
sphingolipid–amyloidogenic-protein
interactions
Structural diversity of membrane
sphingolipids
That the same amyloidogenic protein could
interact with several distinct sphingolipids
(Refs 26, 27, 31) could be viewed as paradoxical
and difficult to reconcile with a real specificity
of interaction. A biochemical analysis of
sphingolipid structures is necessary to get a
clearer view on this issue. Sphingolipids are
formed by the condensation of a fatty acid chain
with a sphingoid base (which is generally
sphingosine although five different sphingoid
bases have been detected in mammalian cells).
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sThe biochemical diversity of sphingolipids is first
generated by the numerous fattyacids (more than
20, varying in chain length, degree of saturation
a n dd e g r e eo fh y d r o x y l a t i o n )t h a tc a nb ea t t a c h e d
to the sphingoid base to form a ceramide
(Ref. 40). Sphingolipids are then classified into
sphingomyelin and glycosphingolipids, according
to the biochemical nature of the polar part
attached to ceramide: phosphorylcholine for
sphingomyelin, and a glycan moiety for
glycosphingolipids. Several hundred different
carbohydrate structures have been described in
glycosphingolipids, with various combinations
of neutral sugars, sulfated sugars and sialic
acids (Ref. 19).
Cracking the code governing
glycosphingolipid–protein interactions
Despite this huge structural diversity,
glycosphingolipids can share common structural
fingerprints that render them ‘readable’ by the
same protein. This is the case for the
glycosphingolipids GalCer, globotriaosylceramide
(Gb3) and GM3, which have a distinct sugar
moiety but a common galactosyl residue with
the same orientation (Fig. 3a–c). As a logical
consequence of this common structural feature,
a protein that recognises one of these
glycosphingolipids (e.g. GalCer), through
binding to this galactose residue, might also
interact with the other two (in this case, Gb3
and GM3). This means that the biochemical
code governing glycosphingolipid–protein
interactions is degenerate. An example of this
striking property is the V3 loop domain of the
human immunodeficiency virus 1 (HIV-1)
surface-envelope glycoprotein gp120, which was
shown to recognise first GalCer (Refs 41, 42, 43),
and then, several years later, both Gb3 and GM3
(Refs 44, 45). However, there is a unique
Unstructured monomers
Ld phase Lo phase
3D
2D
Sphingolipid
Cholesterol
ab
Neuronal membranes as concentration platforms and chaperones for 
amyloidogenic monomers: key role of sphingolipid–cholesterol domains
Expert Reviews in Molecular Medicine © Cambridge University Press 2010
Figure 2. Neuronal membranes as concentration platforms and chaperones for amyloidogenic
monomers: key role of sphingolipid–cholesterol domains. (a) Amyloidogenic monomers have a low
affinity for the liquid-disordered (Ld) phase of plasma membranes enriched in phosphatidylcholine. (b) By
contrast, the monomers have a high affinity for sphingolipid–cholesterol domains in the liquid-ordered (Lo)
phase. In this case, monomers are not only concentrated on the membrane surface, but also undergo a
major conformational change induced by the sphingolipids. This property is referred to as the chaperone
effect of sphingolipids on amyloidogenic proteins.
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smolecular mechanism that accounts for the
interaction of each of these glycosphingolipids
with gp120 (Ref. 46), and this mechanism also
applies for amyloidogenic proteins.
Let us first consider the way in which proteins
bind to GalCer, which is both the major lipid of
myelin sheaths (Ref. 47) and the simplest
possible brain-expressed glycosphingolipid,
consisting of a ceramide linked to a single
galactosyl group (i.e. a ceramide monohexoside).
Most of the GalCer molecule is dipped into the
membrane, so that the galactosyl moiety is the
principal region of the glycolipid available for
protein binding. In this respect, there is a
functional similarity between proteins that
recognise GalCer and galactose-specific lectins.
However, the local concentration of galactosyl
groups in a nanodomain of GalCer is extremely
high compared with the maximal concentration
of free galactose in biological fluids (another
illustration of the reduction-in-dimensionality
concept discussed above). This explains why
even high concentrations of free galactose
cannot inhibit GalCer–gp120 interactions
(Ref. 41). Moreover, the conformation of the
galactose head group in the glycolipid is
restricted by the ceramide backbone, which
allows only limited motion of the sugar
Gb3 GM3 GalCer
Phe
Gal
Cer
GalCer-NFA
Chol
α-OH α-OH α-OH
Gal
Gal
Gal
ab c
e
d
Glycosphingolipids and amyloidogenic proteins: a common mechanism of 
interaction?
Expert Reviews in Molecular Medicine © Cambridge University Press 2010
Figure 3. Glycosphingolipids and amyloidogenic proteins: acommon mechanism of interaction? Despite
their high level of biochemical diversity, some glycosphingolipids share a common galactosyl ring with an
orientation compatible with the establishment of stacking CH-π interactions between the sugar and an
aromatic residue. Such galactosyl rings are indicated in shaded circles in the sugar moiety of ganglioside
GM3 (a), globotriaosylceramide Gb3 (b) and galactosylceramide GalCer (c). In these cases, the apolar side
of the galactosyl ring fits particularly well with the aromatic-ring side chain of an aromatic residue (Phe, in
this case) exposed at the surface of an amyloid protein (d). The electronic cloud of the π system stacks
onto the CH groups of the galactosyl ring. This interaction is favoured by the common geometric structure
of both rings, which allows a coordinated binding process between CH groups and π electrons.
Cholesterol, which has a strong affinity for sphingolipids, can further improve the accessibility of the
galactosyl group through fine tuning of glycosphingolipid conformation (e). This effect involves the
establishment of an H-bond network between the OH group of cholesterol, the NH group of the
sphingolipid and the oxygen atom of the glycosidic bond linking the ceramide and the sugar part of the
sphingolipid. GalCer-NFA, GalCer with a nonhydroxylated fatty acid in the ceramide moiety.
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s(Ref.48).Bycontrast,galactoseinwatersolutionis
free to adopt a wide range of conformations.
Finally, the most polar part of ceramide, which
includes both amide and hydroxyl (OH) groups,
as well as the β-glycosidic bond linking
ceramide to galactose, can also participate in the
binding reaction and further stabilise the
GalCer–protein complex. Taken together, these
biochemical properties of the galactosyl head
group of GalCer explain why GalCer–protein
interactions are distinct from galactose–lectin
interactions (Ref. 49).
Key role of aromatic residues in
protein–glycosphingolipid interactions
At the molecular level, numerous proteins that
bind to GalCer have a solvent-exposed aromatic
residue that provides a complementary surface
for a stacking interaction with the galactose ring
(Fig. 3d). As a result of the distribution of the
OH groups linked to the pyranosyl ring of
galactose, this sugar has two chemically distinct
faces: one apolar with hydrocarbyl (CH) groups
and the other polar with OH groups. Therefore,
the apolar face of galactose is particularly suited
for a stacking interaction with an aromatic
structure (Ref. 50). This type of interaction
between CH groups and a π-electron cloud
system has been described and referred to as
CH–π interaction by Nishio and co-workers
(Ref. 51). The CH–π stacking mechanism is
involved in the interaction between
glycosphingolipids and several amyloidogenic
proteins, including PrP (Ref. 49), Aβ (Ref. 52)
and amylin (Ref. 53). In both Gb3 and GM3, the
apolar side of the central galactosyl group has a
similar orientation to that in GalCer (Fig. 3a–c);
thus, GalCer-binding proteins are predicted to
also bind to Gb3 and GM3 through CH–π
stacking. Note that the conformation of the
sugar moiety of glycosphingolipids is restricted
by a network of H-bonds (Ref. 52) that involves
either an OH group in the acyl chain of the
ceramide (intramolecular network) or the OH
group of cholesterol (intermolecular network,
Fig. 3e), as further discussed below (see the
section ‘The outside and inside effects of
cholesterol’).
The notion that unrelated proteins, displaying a
solvent-accessible aromatic residue in a hairpin
domain, might bind these glycosphingolipids
through a similar stacking mechanism has
motivated the search for V3-like domains in
various proteins, including amyloidogenic
proteins (Ref. 27). This is the concept of the
glycosphingolipid-binding domain or, more
generally, of the sphingolipid-binding domain
(Ref. 49). Such domains are characterised by the
presence, in a flexible region of the surface of a
protein, of an aromatic residue with its side
chain oriented towards the solvent, as illustrated
in Figure 4a with the superimposition of the
glycosphingolipid-binding domains of Aβ and
α-synuclein (Ref. 31). The recognition of the
glycosphingolipid by this region of the protein
is thought to proceed through an induced-fit
mechanism involving the conformational
mobility of the aromatic side chain and a
concomitant adjustment of the orientation of the
galactosyl head group (Fig. 4b).
In summary, a glycosphingolipid-binding
domain is a flexible domain containing turn-
inducing (Gly, Pro), basic (Arg, Lys, His) and
aromatic residues (Phe, Tyr, Trp) (Refs 27, 54, 55,
56, 57). The critical involvement of aromatic
residues in the interaction between proteins and
glycosphingolipids has been convincingly
demonstrated by using synthetic peptides in
which these residues were replaced by Ala or
Leu (Refs 53, 54, 55): correspondingly, the
interaction with the glycosphingolipid has been
dramatically decreased or even totally lost.
Reciprocally, conservative aromatic substitutions
(e.g. Phe to Trp) did not affect binding to
glycosphingolipids (Ref. 54). Taken together,
these data show that the sphingolipid-
binding domain mediates specific protein–
glycosphingolipid interactions driven by CH–π
stacking of a sugar and aromatic residue
(Refs 52, 58).
Glycosphingolipids exert a chaperone
effect on amyloidogenic proteins
Conformational changes mediated by
sphingolipid-binding domains
One important consequence of protein–
sphingolipid interactions is that the
conformation of the protein can be significantly
affected on binding to sphingolipids (Fig. 4b).
This chaperone effect of sphingolipids is a direct
consequence of the unique modalities of
protein–sphingolipid interactions (Ref. 49). As
soon as binding begins, the structure of the
sphingolipid changes and the protein gradually
adapts its shape to this moving target. A stable
anchoring of the protein to the sphingolipids
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scan be obtained by optimising protein–
sphingolipid contacts, and this requires
significant conformational changes of the
protein. The flexibility of the sphingolipid-
binding domain is particularly well suited to
trigger structural rearrangements in the protein
(Ref. 49). This unexpected consequence of
protein–sphingolipid interactions has been
extensively studied with HIV-1. Briefly, on
binding to raft glycosphingolipids through its
V3 domain, HIV-1 gp120 undergoes a series of
conformational changes that are required for
virus fusion (Refs 19, 45). Because the
sphingolipid-binding domain is evolutionarily
conserved (it has been found in virus, bacteria,
insect and mammalian proteins), it is likely that
sphingolipids can modulate the conformation
and regulate the function of a wide range of
proteins (Refs 52, 53, 54, 55, 56, 57).
Chaperone effect of ganglioside GM1 on
Alzheimer Aβ peptides
How could this concept of a sphingolipid-
mediated chaperone effect apply to membrane-
bound amyloids? Seminal work by Matsuzaki,
Yanagasiwa and co-workers has shown that
lipid rafts act as surface catalysts able to
accelerate the aggregation of Aβ (Refs 29, 59, 60,
61, 62, 63). Most interestingly, GM1-bound Aβ
has been identified as a pre-amyloid form acting
*
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A common sphingolipid-binding domain in amyloidogenic proteins
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Figure 4. A common sphingolipid-binding domain in amyloidogenic proteins. (a) Amyloidogenic proteins
share acommon sphingolipid-binding domain, which can be shown bysuperimposing the structure of micelle-
bound Alzheimer Aβ peptide [PDB ID: 1BA4, in red] (Ref. 150) onto the structure of micelle-bound α-synuclein
[PDB ID: 1XQ8, in blue] (Ref. 142). The motif corresponds to a helix–turn–helix structure displaying an aromatic
residue (Tyr10 for Aβ; Tyr39 for α-synuclein) oriented towardsthe solvent and located at a similar position in the
loop. The location of Glu residues associated with Glu to Lys mutations in genetic forms of Alzheimer and
Parkinson diseases is indicated (Glu22 for Aβ and Glu46 for α-synuclein, respectively). The amino acid
sequence of both proteins (upper panel) show very little homology, apart from the above-mentioned Tyr
residues (asterisk) and a common Val residue (Val52 for α-synuclein and Val24 for Aβ). (b) Due to the high
conformational plasticity of amyloidogenic proteins, the sphingolipid-binding domain can adopt several
distinct conformations, as shown for the core amyloid-forming motif of amylin [NFGAILSS octapeptide,
PDB ID: 1KUW] (Ref. 68). The α-carbon chain of the peptide is coloured in blue, and the Phe residue in red.
Twenty conformers obtained by nuclear magnetic resonance (NMR) analysis are superposed. Once bound
to the glycosphingolipid (GSL, coloured in green), the amyloid peptide is locked in a unique conformation.
Cholesterol (Chol) is coloured in orange. This drawing is based on data in Ref. 53 obtained with
lactosylceramide (LacCer).
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sas an endogenous seed for the formation of
neurotoxic amyloid fibrils in Alzheimer disease
(Refs 29, 61, 62, 63). These data have not only
strengthened the role of lipid rafts as
preferential binding sites for unstructured
amyloidogenic proteins on neuronal membranes
but have also suggested that these membrane
domains behave as conformational catalysts for
amyloid formation. In other words, lipid rafts
can control the conformation of membrane-
bound amyloid through a chaperone effect
(Refs 49, 59, 64). Yet, conflicting data have
suggested that binding of Aβ to GM1 induces a
conformational transition from random coil to a
protective α-helical structure (Ref. 65), as also
observed for α-synuclein (Ref. 30), or to a
fibrillation-prone β-structure (Refs 61, 66). The
structure of amyloidogenic proteins bound to
GM1 depends on several physicochemical
parameters, including pH, membrane fluidity,
GM1-carrier lipid ratios, protein concentration
and the absence or presence of cholesterol,
which could explain the discrepancies reported
in the literature. In any case, the available data
suggest that lipid rafts could (1) modulate the
conformational changes of unstructured
monomers from the unfolded state to more-
ordered α or β structures, and (2) control the
balance between α and β structures, which in
turn determine the oligomerisation/aggregation
status of amyloidogenic proteins.
Kakio et al. (Ref. 59) have shown that the
oligomerisation and aggregation of Aβ peptides
occur in ganglioside-enriched domains of the
plasma membrane. A possible sequence of
events could be as follows: (1) soluble Aβ
monomers bind to the sugar head group of
gangliosides in cholesterol–sphingolipid-
enriched domains such as lipid rafts; (2) on
binding to gangliosides, Aβ is constrained to
adopt an α-helical structure; (3) as the protein
density on the membrane increases, Aβ
undergoes a conformational transition from an
α-helix-rich structure to a β-strand-rich one; and
(4) the ganglioside-bound Aβ complex with
acquired secondary structures serves as a seed
for amyloid fibril formation. Indeed, Aβ fibrils
with high toxicity have been successfully
generated in an acellular system using GM1-
containing raft-like liposomes (Ref. 67).
Altogether, these data strongly support the
concept that the ganglioside cluster can act as a
chaperone able to lower the activation energy
for the conformational changes of Aβ (Ref. 59).
This scenario is also consistent with the
involvement of the glycosphingolipid-binding
domain in membrane–amyloid interactions
(Refs 53, 64).
How glycosphingolipids could stabilise an
α-helix and prevent amyloid formation
Unstructured amyloidogenic proteins can adopt a
wide range of conformations in water and
in biological membranes (Fig. 1). The
conformational flexibility of the amyloid core
peptide of amylin (NFGAILSS) has been studied
by nuclear magnetic resonance (NMR) (Ref. 68).
In a membrane-like micellar environment, this
peptide can adopt three distinct classes of
conformations owing to the wide flexibility of
the peptide chain (Fig. 4b). Correspondingly, the
unique Phe residue of the motif has three main
possible orientations (Ref. 53). On binding to a
glycosphingolipid bearing an appropriately
oriented galactosyl group (lactosylceramide in
Fig. 4b), the Phe residue stacks onto the sugar
so that only one of the numerous peptide
conformations is selected and locked.
This illustrates the potency of CH–π stacking
interactions to stabilise a thermodynamically
unstable conformation at a minimal energetic
cost, just like a wedge can efficiently block a car
on a sloping street (Ref. 49). This simple but
efficient mechanism could allow raft
glycosphingolipids to act as molecular
chaperones inducing α-helix-rich structures in
amyloidogenic proteins (Fig. 5). In the case of
PrP, the stabilisation of an α-helix structure is
beneficial, because this can prevent protein
misfolding and aggregation (Ref. 49). However,
the α-helix conformation could also facilitate
membrane insertion and channel/pore
formation, leading to dramatic perturbations of
membrane permeability, as shown for α-
synuclein (Ref. 69). In addition, the chaperone
effect of glycosphingolipids is not irreversible.
Changing the physicochemical properties of the
raft–protein complex, for example through
oxidative damage to the proteins or lipids
(Refs 70, 71), could theoretically induce the
dissociation of the amyloid peptides from
glycosphingolipids such as GalCer. Then, the
sudden exposure of aromatic side chains would
allow a tight packing (through π–π interactions)
between adjacent helices. This would lead to the
formation of a dimer, a key step in the
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sgenerationofamyloidfibrils(Refs72,73),whichis
thought to proceed through an ordered
polymerisation of β structures (Ref. 74).
From this discussion, we would like to
underscore (1) the key role of aromatic residues
in the self-assembly of amyloid fibrils and (2)
the chaperone effect of raft glycosphingolipids
that could induce otherwise thermodynamically
unstable α-helix structures of amyloid fibril-
forming proteins. Indeed, most amyloidogenic
proteins (including Aβ and PrP) have an amino
acid sequence that is expected to form β but not
α structures (Ref. 75). These proteins are referred
to as ‘α-helix/β-strand discordant’. Lipid rafts
can prevent those proteins from adopting the
conformation they prefer, stabilising their
structure in a ‘forced’ α conformation. This
stabilisation can occur in the early biosynthetic
pathway as demonstrated for PrP (Ref. 76).
Inhibition of sphingolipid biosynthesis logically
increases PrP misfolding into disease-associated
β structures (Ref. 77). This mechanism seems to
also apply for several neurotransmitter receptors
(e.g. the nicotinic acetylcholine receptor) whose
transport and assembly in the plasma
membrane require the assistance of sphingolipids
(Ref. 78). Mutations in amyloidogenic proteins
that are associated with inherited forms of
GSL
GSL and
α-helix protein conformation
α-Helix
conformation
β-Strand
conformation
CH–π
π–π
Aromatic
attraction
ab
How glycosphingolipids could promote α-helix structures in amyloidogenic 
proteins
Expert Reviews in Molecular Medicine © Cambridge University Press 2010
Figure 5. How glycosphingolipids could promote α-helix structures in amyloidogenic proteins. When
bound to glycosphingolipids (GSLs) through the sphingolipid-binding domain, the aromatic residues of two
vicinal amyloidogenic proteins cannot interact with each other and the protein is forced to adopt an α-helix
conformation. The molecular mechanism of this interaction is the CH–π stacking between the galactosyl
ring of GalCer and the aromatic residue of the protein. The α-helix structure of amyloidogenic proteins is
not only present in membrane-bound monomers (as illustrated in Fig. 2, right panel), but also in oligomeric
α-synuclein channels (Fig. 1g). The β-amyloid aggregation process is triggered when the glycosphingolipid–
protein complex is destabilised, resulting in the release of the protein from its glycosphingolipid chaperone
(a). In this new glycosphingolipid-free environment, the aromatic residues of two vicinal amyloidogenic
proteins can interact together (b), inducing a drastic conformational change from an initial α-helix to a
β-strand structure. Amyloid aggregation then results from the π–π-driven assembly of aromatic side chains
(for a review, see Ref. 79), forming amyloid dimers that in turn associate to form amyloid fibrils (as
illustrated in Fig. 1e).
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to directly affect sphingolipid binding. This
is the case for the Creutzfeldt–Jakob-linked
E200K mutation of PrP, which affects
PrP–sphingomyelin interactions (Ref. 27).
In summary, by providing a complementary
surface for amyloidogenic proteins, cellular
glycosphingolipids might constitutively stabilise
their α conformation and inhibit their
aggregation, as recently demonstrated for
amylin (Ref. 53). Replacing these
glycosphingolipid–protein CH–π interactions
with protein–protein π–π interactions (Refs 18,
50) would then trigger amyloid growth and
deposition (Refs 49, 79). To what extent
glycosphingolipids could also stimulate β-
strand-mediated amyloid aggregation (Ref. 59)
remains to be described and explained at the
molecular scale. The mutual effect of GM1 and
Aβ on their respective conformations is likely to
displace the equilibrium of the reaction towards
the formation of amyloid aggregates, as
observed in vitro (Ref. 80).
Finally, it should be noted that noncovalent
interactions distinct from CH–π stacking might also
contribute to sphingolipid–amyloid interactions.
These could include hydrophobic interactions
(Ref. 81), H-bonds and electrostatic bridges
(especially for sulfated glycosphingolipids,
gangliosides and sphingomyelin) (Ref. 82).
Indeed, in addition to aromatic side chains
(Tyr10), several aliphatic (Ref. 81) and basic
residues such as His13 have been implicated in
GM1–Aβ interactions (Ref. 83). Anionic
phospholipids such as phosphatidylserine,
which bind to α-synuclein through electrostatic
interactions (Ref. 38) and stimulate the
formation of amyloid fibres (Ref. 84), could, in
the cytoplasmic leaflet of the plasma membrane,
have a role equivalent to the one played by
gangliosides in the external leaflet.
The outside and inside effects of
cholesterol
Cholesterol as arisk factorand atherapeutic
target for neurodegenerative diseases
Highcholesterolhasbeenidentifiedasamajorrisk
factor for both Alzheimer (Ref. 85) and Parkinson
(Ref.86)diseases,anddysregulationofcholesterol
homeostasis is a hallmark of neurodegenerative
diseases (Ref. 87). Unfortunately, the effects of
cholesterol on amyloid fibrillogenesis and
toxicity are not well understood and the results
reported so far are controversial (Ref. 88).
Cholesterol directly binds to APP (Ref. 89) and
stimulates its insertion into phospholipid
monolayers (Ref. 90). It also binds to Aβ
protofibrils (Ref. 91). However, whether
cholesterol accelerates (Ref. 92) or decreases
(Refs 93, 94) Aβ polymerisation is still uncertain.
Moreover, the generation of Aβ peptides
through APP proteolysis occurs within lipid
rafts and is sensitive to inhibitors of cholesterol
biosynthesis (Ref. 95), so that the involvement of
cholesterol homeostasis in Alzheimer disease
cannot be simply ascribed to the regulation of
Aβ fibrillogenesis.
In the case of Parkinson disease, data obtained
with both cultured neuronal cells and transgenic
mice have shown that the cholesterol-depleting
agent methyl-β-cyclodextrin decreased the level
of α-synuclein in membrane fractions (Ref. 96).
Moreover, metabolic inhibition of cholesterol
biosynthesis with statins reduced the levels of α-
synuclein accumulation in neuronal membranes,
whereas cholesterol supplementation of cultured
neurons increased α-synuclein aggregation
(Ref. 97). Consistent with these studies, it was
recently reported that lovastatin treatment of α-
synuclein transgenic mice was associated with a
marked reduction of α-synuclein aggregation
and abrogation of neuronal pathology (Ref. 98).
This suggests that treatment with cholesterol-
lowering agents might be beneficial for patients
with Parkinson disease. It has been suggested
that oxidised cholesterol metabolites could
accelerate α-synuclein aggregation (Ref. 71), which
provides a mechanistic link between oxidative
stress and Parkinson disease. Yet the molecular
mechanisms by which cholesterol and/or its
metabolites could affect the oligomerisation/
aggregation status of amyloidogenic proteins
have not been fully deciphered. Recent
physicochemical data could shed some light on
this complex issue.
Effects of cholesterol on sphingolipid
conformation
First, cholesterol has a major impact on the
conformation of sphingolipids. The apolar part
of sphingolipids (i.e. the most important part of
the ceramide) interacts with the smooth face of
cholesterol, whereas the OH group of cholesterol
is accessible to the polar part of the sphingolipid
(Ref. 18). In the case of glycosphingolipids, this
OH group is involved in an H-bond network
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sthat restricts the conformation of the sugar moiety
in a parallel orientation with respect to the
membrane. This effect is particularly important
when the ceramide contains a nonhydroxylated
fatty acid (NFA, Fig. 3e). Because this
conformation of the sphingolipid is particularly
suited for a sphingolipid-binding domain,
cholesterol usually accelerates protein binding to
sphingolipid (Ref. 99) and this also applies for
amyloidogenic proteins (Ref. 52). By contrast,
when the sphingolipid contains a hydroxylated
fatty acid (HFA), the OH group of cholesterol is
excluded from the H-bond network and it
cannot exert its conformational effect on the
sphingolipid. In this case, cholesterol does not
improve but rather perturbs the organisation of
sphingolipids and can even inhibit
glycosphingolipid binding to amyloidogenic
proteins (Ref. 52). Thus, according to the
distribution of HFAs versus NFAs in
sphingolipids, an increase of membrane
cholesterol can lead to opposite effects on
sphingolipid-mediated amyloidogenic protein
binding and aggregation. In any case, these
effects are due to a fine tuning of sphingolipid
conformation induced by cholesterol, and do not
involve any kind of physical interaction between
amyloidogenic proteins and cholesterol.
Amyloidogenic proteins interact first with
sphingolipids and then with cholesterol
By contrast, the second mechanism involves a
direct interaction between the amyloidogenic
protein and cholesterol. Therefore, this effect
requires the insertion of a part of the amyloid
protein in the membrane; otherwise the protein
would not be in physical contact with
cholesterol. Devanathan et al. (Ref. 100) have
shown that Aβ peptide aggregation on the
bilayer surface requires a sphingomyelin-rich
environment but can occur in the absence of
cholesterol. This is in line with our hypothesis
that sphingolipids are fully responsible for the
initial binding of amyloidogenic proteins to lipid
rafts, and that cholesterol is not directly
involved at this stage. However, at the second
step the presence of cholesterol may greatly
facilitate peptide insertion into the bilayer. The
preferential interaction of amyloidogenic
proteins with lipid raft domains ensures that
cholesterol is indeed present underneath the
sphingolipids that have attracted the
unstructured monomer (Fig. 6). Once inserted in
the membrane, the amyloidogenic protein will
immediately find cholesterol and interact with
its free side – that is, the face that is not in
contact with sphingolipids (for a detailed
explanation of cholesterol topology, see Ref. 18).
How cholesterol could regulate the
formation of oligomeric pores and channels
By stimulating the oligomerisation of membrane-
inserted amyloidogenic proteins, cholesterol
could facilitate the formation of a pore-like
assembly displaying ion channel properties
(Fig. 1). Quist et al. (Ref. 10) have hypothesised
that amyloid pore/channels provide the most
direct pathway for inducing neurodegenerative
effects, through loss of ionic homeostasis
increasing cell calcium to toxic levels. The
structure of amyloid pores, which have been
observed by atomic force microscopy (Refs 9,
10), remains to be experimentally elucidated at
the atomic level. Computational models have
suggested that most amyloid pores are probably
formed by a complex assembly of β-rich
protofibrils or oligomers (Ref. 130), as shown in
Figure 1. However, in the case of α-synuclein,
Tsigelny et al. (Ref. 101) have elegantly
modelled a realistic oligomeric channel formed
by the assembly of α-helical monomers. The
possible events leading to the formation of an α-
synuclein oligomeric channel under the dual
control of sphingolipids and cholesterol are
summarised in Figure 6. There is a striking
similarity between α-synuclein (Refs 69, 31) and
colicin E1, a bacterial toxin that also inserts into
anionic areas of the plasma membrane, forming
channel-like structures consisting of an α-helix
bundle (Ref. 102). Moreover, it has been
hypothesised that amyloid pores might be
similar to β-barrel pore-forming bacterial toxins
(Ref. 103). Since cholesterol controls the
oligomerisation and insertion of these bacterial
toxins (Ref. 104) in the target membrane, it is
likely that it is also required for the assembly of
amyloid pores.
How could cholesterol control the
oligomerisation process of membrane-inserted
amyloidogenic proteins and facilitate the
formation of amyloid pores? The recent high-
resolution crystal structure of an engineered
human adrenergic β2 receptor, suggesting a
molecular mechanism by which cholesterol
mediates receptor dimerisation (Ref. 105),
might give some clues to this fundamental issue.
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hypothesise that cholesterol binds to membrane-
embedded fragments of amyloidogenic proteins,
facilitates their recruitment and coordinates their
oligomerisation. Overall, this would mean that
amyloid pore formation and ion channel
function are under the control of both
sphingolipids and cholesterol, in agreement
with recent data obtained in model membranes
with α-synuclein (Ref. 31) and amylin (Ref. 106).
Finally, it has been reported that spherical
amyloid oligomers or protofibrils can also
increase membrane conductance without
forming ion channels or pores (Ref. 107). It is
not known if cholesterol and/or sphingolipids
are involved in this nonspecific permeabilising
activity.
Changes in lipid content of the brain: what
impact on neurodegenerative diseases?
The involvement of gangliosides in several
neurodegenerative diseases is not totally
surprising if one considers that these
sphingolipids are critical for neuronal integrity
and plasticity (Ref. 108) and synaptic function
(Ref. 109). Since the probability of acquiring
these diseases gradually increases with age, it is
important to evaluate how ganglioside
Ca2+
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-
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-
-
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-
-
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Glycosphingolipid
Cholesterol
Lipid-dependent formation of an α-synuclein oligomeric channel
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Figure 6. Lipid-dependent formation of an α-synuclein oligomeric channel. Unfolded α-synuclein
monomers (a) are attracted by the polar heads of glycosphingolipids and concentrated on the surface of
sphingolipid–cholesterol membrane domains (b). Sphingolipids, complexed with cholesterol, induce a
conformational change (unstructured to α-helix transition) of α-synuclein. The newly formed α-helices can
insert into the plasma membrane (c) where they can further oligomerise under the control of cholesterol
molecules (blue arrows) (d) and eventually form an oligomeric ion channel. Such channels are thought to
disturb membrane permeability to calcium ions (red arrows), resulting in neuronal dysfunction and toxicity.
The minus signs (in red) refer to the negative charges of α-synuclein.
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sexpression varies during the lifetime of
individuals, and whether these diseases can
alter this process (Ref. 110). In vitro, the
differentiation of PC12 cells into neuron-like
cells caused a marked increase in both
gangliosides and cholesterol, and thereby
greatly potentiated the accumulation and
cytotoxicity of Aβ (Ref. 111). GM1 seems to
control the oligomerisation and aggregation
process of Aβ and α-synuclein (Refs 29, 30, 31).
GM3 has been shown to control α-synuclein
channel formation and to correct the
channelopathy induced in planar lipid
membranes by the Parkinson-disease-linked
E46K mutant of the protein (Ref. 31). In the
human brain, GM3 is a minor ganglioside,
which, in marked contrast with the major
ganglioside species GM1 and GD1A, shows a
regular increase with age (Ref. 112). The
expression of GM3 is highly regulated during
brain development (Ref. 113), and this
ganglioside has been implicated in the
regulation of neuronal cell death (Ref. 114).
Moreover, the homozygous loss-of-function
mutation of GM3 synthase, which totally
suppresses the expression of GM3 and all GM3-
derived gangliosides, has been linked to an
infantile symptomatic epilepsy syndrome
(Ref. 115). Taken together, these data indicate
that ganglioside GM3 probably plays a more
important role in brain physiology and
pathology than its low expression levels in adult
brain could have suggested in the past.
Several studies support the view that
deregulation of lipid metabolism is an important
feature of neurodegenerative diseases. The three
main lipid categories – glycerophospholipids,
sphingolipids and cholesterol – are affected
(Refs 116, 117, 118, 119, 120, 121). A large body
of data has established a link between
cholesterol homeostasis, apolipoprotein E
polymorphism and APP processing (Ref. 122).
Correspondingly, cholesterol-lowering strategies
with statins have acquired potential therapeutic
importance in treating Alzheimer disease
(Ref. 123), although success has been variable
(Ref. 124). Statins have also proved to be
efficient in decreasing α-synuclein aggregation
and neuronal toxicity in animal models of
Parkinson disease (Ref. 98). Specific changes in
ganglioside content have been detected in the
brains of patients with Alzheimer disease
(Refs 116, 125): a decrease or even loss of the
major gangliosides GM1, GD1a, GD1b and
GT1b, and an increase in GM2, GM3 and GD3.
Similar alterations of ganglioside expression
were observed in the brains of transgenic mouse
models of Alzheimer disease (Ref. 126). Regional
variations in ganglioside content have been
shown in Alzheimer brains (Ref. 127). Moreover,
the balance between NFA and HFA ceramides is
altered in animal models (Ref. 128).
Interestingly, the authors of the latter study
showed that there is a gender-dependent
accumulation of ceramides in the cerebral
cortex: female mice exhibited a strong increase
in HFA species, and males in NFA species. This
observation could be linked to the increased risk
of women versus men for developing Alzheimer
disease (Ref. 129). Because cholesterol can exert
distinct effects on Aβ–membrane interactions
according to the NFA:HFA content of brain
sphingolipids (Ref. 52), it will be interesting to
determine how cholesterol impacts on
Aβ–glycosphingolipid interaction in men and
women suffering from Alzheimer disease.
Perspectives
How amyloidogenic proteins kill neurons is still a
mystery. In particular, as recently discussed by
Butterfield and Lashuel (Ref. 130), ‘there remains
a knowledge gap regarding the molecular-level
details by which amyloid-forming proteins act
on the membrane and induce membrane
permeabilization’. Deciphering the complex
interplay between amyloidogenic proteins and
membrane lipids, especially sphingolipids and
cholesterol, will certainly help to achieve a
clearer view on this enigma. Several milestones
have already been reached, which have inspired
an important part of today’s research efforts
worldwide. Despite their lack of amino acid
sequence homology, amyloidogenic proteins
share a number of intriguing properties: (1) an
important conformational plasticity, allowing the
same protein to remain unordered or to form
highly ordered α and β structures (Refs 4, 5);
(2) self-oligomerising capacities that revealed
unexpected common antigenic properties
(Ref. 7); (3) the ability to form pore-like
structures with ion channel properties (Refs 9,
10); (4) self-aggregating activity leading to
fibrillation and plaque deposition (Ref. 131);
and (5) common structural motifs allowing
specific interactions with sphingolipids (Ref. 49)
and cholesterol (yet uncharacterised) in lipid
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sraft domains of the plasma membrane. It is
intriguing that HIV-1, which interacts with
glycosphingolipids through the V3 domain of its
surface glycoprotein gp120, can induce major
neurological disabilities, identified as HIV-1-
associated dementia (Ref. 110). In this respect, it
is also worth noting that the protein CLN3,
involved in Batten disease (the juvenile form of
neuronal ceroid lipofuscinosis), also binds to
GalCer through a V3-like sphingolipid-binding
domain (Ref. 132). This neural disease is caused
by a mutation in this domain, namely E295K
(Ref. 133), which is analogous to mutations
E22K in Aβ, E46K in α-synuclein and E200K in
PrP, all associated with inherited forms of
neurodegenerative disease and located in the
sphingolipid-binding domains of these proteins.
At least for two of these proteins (PrP and
α-synuclein), the substitution of an anionic
glutamic acid side chain by a cationic lysine
resulted in altered binding to membrane
sphingolipids (Refs 27, 31). This further
emphasises the key role of the sphingolipid-
binding domain in neuronal diseases.
Future studies will be necessary to better
evaluate the neurotoxicity of the various forms
of amyloidogenic proteins, including monomers,
oligomers and aggregates, and to understand
how these different species cooperate to
accelerate (or slow down) the onset of
neurodegenerative symptoms. This will help to
decide on a rational basis which therapeutic
strategy should be used at the different stages of
the diseases. This will be possible with the
finding of nontoxic drugs specifically affecting
amyloid channels (Ref. 134) or amyloid
aggregation (Ref. 135). Combining molecular
(Refs 31, 52), biophysical (Refs 14, 31, 69, 136,
137), cellular (Refs 93, 114, 138) and animal
(Refs 126, 128, 139) studies will allow a better
characterisation of the sphingolipids that
regulate amyloid oligomerisation/aggregation.
Biophysical properties of the membrane such as
membrane curvature should be taken into
consideration (Ref. 130). Indeed, depending on
the surface curvature of the model membrane,
membrane-bound α-synuclein can adopt an
extended helix (Ref. 140), a bent helix (Ref. 141)
or an antiparallel helix–turn–helix conformation
(Ref. 142) (for a review see Ref. 130).
Interestingly, GM1 and GM3 are concentrated in
membrane areas that markedly differ in
membrane curvature (Ref. 143), so that on
binding to distinct gangliosides, the same
amyloid protein could adopt distinct
conformations. This could be the case for α-
synuclein, which recognises both GM1 (Ref. 30)
and GM3 (Ref. 31). Antiganglioside antibodies
could interfere with normal ganglioside function
and could thus play a role in disease
pathogenesis, as anti-GM1 antibodies probably
do in some Parkinson patients (Refs 110, 144).
Careful determinations of the titres of these
antibodies in various biological fluids, including
cerebrospinal fluid, will be particularly
informative. Beneficial effects of ganglioside
supplementation have been reported in animal
models of Parkinson disease (Ref. 145). This
warrants further investigation. Enzymes
involved in glycosphingolipid metabolism might
represent targets that inhibit both the
production and amyloid aggregation of
Alzheimer Aβ peptides (Ref. 146).
Correspondingly, lipid raft disruption has been
shown to protect neurons against amyloid
oligomer toxicity in vitro (Ref. 147). We need to
better understand how cholesterol interacts with
amyloidogenic proteins, regulates their
supramolecular structures and is involved in the
pathophysiology of neurodegenerative diseases
(Refs 86, 87). We should also determine how
mutations of amyloidogenic proteins affect their
interaction with neural membranes (Refs 27, 69,
148). A decisive breakthrough will be to
understand why neurodegenerative diseases
involve specific brain areas, and how local lipid
composition may account for such geographic
restrictions (Refs 127, 135). Finally, we have to
identify the environmental molecules (such as
food contaminants, pesticides and mycotoxins)
that could modulate amyloid formation through
direct binding to amyloid proteins and could
represent important risk factors for
neurodegenerative diseases (Ref. 149).
Acknowledgements and funding
The authors thank the peer reviewers for their
interest in this work and their very constructive
and thoughtful comments, which have stimulated
us to improve our manuscript.
References
1 Wright, P.E. and Dyson, H.J. (1999) Intrinsically
unstructured proteins: re-assessing the protein
structure-function paradigm. Journal of Molecular
Biology, 293, 321-331
expert reviews
http://www.expertreviews.org/ in molecular medicine
15
Accession information: doi:10.1017/S1462399410001602; Vol. 12; e27; September 2010
©Cambridge University Press 2010. Re-use permitted under a Creative Commons Licence – by-nc-sa.
M
o
l
e
c
u
l
a
r
i
n
s
i
g
h
t
s
i
n
t
o
a
m
y
l
o
i
d
r
e
g
u
l
a
t
i
o
n
b
y
m
e
m
b
r
a
n
e
c
h
o
l
e
s
t
e
r
o
l
a
n
d
s
p
h
i
n
g
o
l
i
p
i
d
s
:
c
o
m
m
o
n
m
e
c
h
a
n
i
s
m
s
i
n
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
s2 Uversky, V.N. (2010) The mysterious unfoldome:
structureless, underappreciated, yet vital part of
any given proteome. Journal of Biomedicine and
Biotechnology 2010, 568068
3 Dunker, A.K. and Uversky, V.N. (2008) Signal
transduction via unstructured protein conduits.
Nature Chemical Biology, 4, 229-230
4 Uversky, V.N. et al. (2009) Unfoldomics of human
diseases: linking protein intrinsic disorder with
diseases. BMC Genomics 10, S7
5 Uversky, V.N. (2003) A protein-chameleon:
conformational plasticity of alpha-synuclein, a
disordered protein involved in neurodegenerative
disorders. Journal of Biomolecular Structure and
Dynamics 21, 211-234
6 Ghahghaei, A. and Faridi, N. (2009) Structure of
amyloid fibrils in diseases. Journal of Biomedical
Science Engineering 2, 345-358
7 Kayed,R.etal.(2003)Commonstructureofsoluble
amyloid oligomers implies common mechanism of
pathogenesis. Science 300, 486-489
8 Glabe, C.C. (2008) Structural classification of toxic
amyloidoligomers.JournalofBiologicalChemistry
283, 29639-29643
9 Lashuel, H.A. et al. (2002) Neurodegenerative
disease:amyloidporesfrompathogenicmutations.
Nature 418, 291
10 Quist, A. et al. (2005) Amyloid ion channels: a
common structural link for protein-misfolding
disease. Proceedings of the National Academy of
Sciences of the United States of America 102,
10427-10432
11 Arispe, N., Rojas, E. and Pollard, H.B. (1993)
Alzheimer’s disease amyloid β-protein forms
channels in bilayer membranes: blockage by
tromethamine and aluminium. Proceedings of the
National Academy of Sciences of the United States
of America 90, 567-571
12 Arispe, N., Rojas, E. and Pollard, H.B. (1994) β-
amyloid Ca2
+-channel hypothesis for neuronal
death in Alzheimer’s disease. Molecular and
Cellular Biochemistry 140, 119-125
13 Vestergaard, M., Hamada, T. and Takagi, M. (2008)
Using model membranes for the study of amyloid
beta:lipid interactions and neurotoxicity.
Biotechnology and Bioengineering 99, 753-763
14 Munishkina, L.A. and Fink, A.L. (2007)
Fluorescence as a method to reveal structures and
membrane-interactions of amyloidogenic proteins.
Biochimica et Biophysica Acta 1768, 1862-1885
15 Hardy, J.A. and Higgins, G.A. (1992) Alzheimer’s
disease: the amyloid cascade hypothesis. Science
256, 184-185
16 Prusiner, S. (1998) Prions. Proceedings of the
National Academy of Sciences of the United States
of America 95, 13363-13383
17 Cabin, D.E. et al. (2002) Synaptic vesicle depletion
correlates with attenuated synaptic responses to
prolonged repetitive stimulation in mice lacking
alpha-synuclein. Journal of Neuroscience 22,
8797-8807
18 Fantini, J. and Barrantes, F.J. (2009) Sphingolipid/
cholesterol regulation of neurotransmitter receptor
conformation and function. Biochimica et
Biophysica Acta 1788, 2345-2361
19 Fantini,J.etal.(2002)Lipidrafts:structure,function
and role in HIV, Alzheimer’s and prion diseases.
Expert Reviews in Molecular Medicine 4, 1-22
20 Simons, K. and Ikonen, E. (1997) Functional rafts in
cell membranes. Nature 387, 569-572
21 Lingwood, D. and Simons, K. (2010) Lipid rafts as
a membrane-organizing principle. Science 327,
46-50
22 Drevot, P. et al. (2002) TCR signal initiation
machinery is pre-assembled and activated in a
subset of membrane rafts. EMBO Journal 21,
1899-1908
23 Taïeb, N., Yahi, N. and Fantini, J. (2004) Rafts and
related glycosphingolipid-enriched microdomains
in the intestinal epithelium: bacterial targets linked
to nutrient absorption. Advances in Drug Delivery
Reviews 56, 779-794
24 Adam, G. and Delbrück, M. (1968) Reduction of
dimensionality in biological diffusion processes. In
Structural Chemistry and Molecular Biology (Rich
A. and Davidson N., eds), pp. 198-215, W.H.
Freeman & Co, San Francisco, USA
25 Aisenbrey, C. et al. (2008) How is protein
aggregation in amyloidogenic diseases modulated
by biological membranes? European Biophysical
Journal 37, 247-255
26 Valdes-Gonzalez, T., Inagawa, J. and Ido, T. (2001)
Neuropeptides interact with glycolipid receptors.
A surface plasmon resonance study. Peptides 22,
1099-1106
27 Mahfoud,R.etal.(2002)Identificationofacommon
sphingolipid-binding domain in Alzheimer, prion,
andHIV-1proteins.JournalofBiologicalChemistry
277, 11292-11296
28 Hebbar, S. et al. (2008) A fluorescent
sphingolipid binding domain peptide probe
interacts with sphingolipids and cholesterol-
dependent raft domains. Journal of Lipid Research
49, 1077-1089
29 Yanagisawa, K. et al. (1995) GM1 ganglioside-
bound amyloid beta-protein (A beta): a possible
expert reviews
http://www.expertreviews.org/ in molecular medicine
16
Accession information: doi:10.1017/S1462399410001602; Vol. 12; e27; September 2010
©Cambridge University Press 2010. Re-use permitted under a Creative Commons Licence – by-nc-sa.
M
o
l
e
c
u
l
a
r
i
n
s
i
g
h
t
s
i
n
t
o
a
m
y
l
o
i
d
r
e
g
u
l
a
t
i
o
n
b
y
m
e
m
b
r
a
n
e
c
h
o
l
e
s
t
e
r
o
l
a
n
d
s
p
h
i
n
g
o
l
i
p
i
d
s
:
c
o
m
m
o
n
m
e
c
h
a
n
i
s
m
s
i
n
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
sform of preamyloid in Alzheimer’s disease. Nature
Medicine 1, 1062-1066
30 Martinez, Z. et al. (2007) GM1 specifically interacts
with alpha-synuclein and inhibits fibrillation.
Biochemistry 46, 1868-1877
31 Di Pasquale, E. et al. (2010) Altered ion channel
formation by the Parkinson’s-disease-linked E46 K
mutant of alpha-synuclein is corrected by GM3 but
not by GM1 gangliosides. Journal of Molecular
Biology 397, 202-218
32 Mattei, V. et al. (2004) Prion protein is a component
of the multimolecular signaling complex involved
in T cell activation. FEBS Letters 560, 14-18
33 Sanghera, N. and Pinheiro, T.J. (2002) Binding of
prion protein to lipid membranes and implications
for prion conversion. Journal of Molecular Biology
315, 1241-1256
34 Schmalzbauer, R. et al. (2008) Evidence for an
association of prion protein and sphingolipid-
mediated signaling. Journal of Neurochemistry
106, 1459-1470
35 Jha,S.etal.(2009)Amyloidogenicpropensities and
conformational properties of ProIAPP and IAPP in
the presence of lipid bilayer membranes. Journal of
Molecular Biology 389, 907-920
36 Jo, E. et al. (2000) Alpha-synuclein membrane
interactions and lipid specificity. Journal of
Biological Chemistry 275, 34328-34334
37 Ramakrishnan, M., Jensen, P.H. and Marsh, D.
(2003) Alpha-synuclein association with
phosphatidylglycerol probed by lipid spin labels.
Biochemistry 42, 12919-12926
38 Kubo, S. et al. (2005) A combinatorial code
for the interaction of alpha-synuclein with
membranes. Journal of Biological Chemistry 280,
31664-31672
39 Stöckl, M. et al. (2008) Alpha-synuclein selectively
binds to anionic phospholipids embedded in
liquid-disordered domains. Journal of Molecular
Biology 375, 1394-1404
40 Futerman, A.H. and Hannun, Y.A. (2004) The
complex life of simple sphingolipids. EMBO
Reports 5, 777-782
41 Harouse,J.M.etal.(1991)InhibitionofentryofHIV-
1inneuralcelllinesbyantibodiesagainstgalactosyl
ceramide. Science 253, 320-323
42 Yahi, N. et al. (1992) Galactosyl ceramide (or a
closely related molecule) is the receptor for human
immunodeficiency virus type 1 on human colon
epithelial HT29 cells. Journal of Virology 66,
4848-4854
43 Cook, D.G. et al. (1994) Binding of human
immunodeficiency virus type I (HIV-1) gp120 to
galactosylceramide (GalCer): relationship to the V3
loop. Virology 201, 206-214
44 Hammache, D. et al. (1998) Specific interaction of
HIV-1 and HIV-2 surface envelope glycoproteins
with monolayers of galactosylceramide and
ganglioside GM3. Journal of Biological Chemistry
273, 7967-7971
45 Hammache, D. et al. (1999) Human erythrocyte
glycosphingolipids as alternative cofactors for
human immunodeficiency virus type 1 (HIV-1)
entry: evidence for CD4-induced interactions
between HIV-1 gp120 and reconstituted
membrane microdomains of glycosphingolipids
(Gb3 and GM3). Journal of Virology 73,
5244-5248
46 Delézay, O. et al. (1996) SPC3, a V3 loop-derived
syntheticpeptideinhibitorofHIV-1infection,binds
tocellsurfaceglycosphingolipids.Biochemistry35,
15663-15671
47 Curatolo,W.(1987)Glycolipidfunction.Biochimica
et Biophysica Acta 906, 137-160
48 Nyholm, P.G., Pascher, I. and Sundell, S. (1990) The
effect of hydrogen bonds on the conformation of
glycosphingolipids.Methylatedand unmethylated
cerebroside studied by X-raysingle crystal analysis
and model calculations. Chemistry and Physics of
Lipids 52, 1-10
49 Fantini,J.(2003)Howsphingolipidsbindandshape
proteins: molecular basis of lipid-protein
interactions in lipid shells, rafts and related
biomembrane domains. Cellular and Molecular
Life Sciences 60, 1027-1032
50 Maresca, M. et al. (2008) Controlled aggregation of
adenine by sugars: physicochemical studies,
molecularmodellingsimulationsofsugar-aromatic
CH-pi stacking interactions, and biological
significance. Physical Chemistry and Chemical
Physics 10, 2792-2800
51 Nishio, M. et al. (1995) The CH/pi interaction:
significance in molecular recognition. Tetrahedron
51, 8665-8701
52 Yahi, N., Aulas, A. and Fantini, J. (2010) How
cholesterol constrains glycolipid conformation for
optimal recognition of Alzheimer’s beta amyloid
peptide (Abeta1-40). PLoS One 5, e9079
53 Levy,M.etal.(2006)Theminimalamyloid-forming
fragment of the islet amyloid polypeptide is a
glycolipid-binding domain. FEBS Journal 273,
5724-5735
54 Fantini,J.,Garmy,N.andYahi,N.(2006)Prediction
ofglycolipid-bindingdomainsfromtheaminoacid
sequence of lipid raft-associated proteins:
application to HpaA, a protein involved in the
expert reviews
http://www.expertreviews.org/ in molecular medicine
17
Accession information: doi:10.1017/S1462399410001602; Vol. 12; e27; September 2010
©Cambridge University Press 2010. Re-use permitted under a Creative Commons Licence – by-nc-sa.
M
o
l
e
c
u
l
a
r
i
n
s
i
g
h
t
s
i
n
t
o
a
m
y
l
o
i
d
r
e
g
u
l
a
t
i
o
n
b
y
m
e
m
b
r
a
n
e
c
h
o
l
e
s
t
e
r
o
l
a
n
d
s
p
h
i
n
g
o
l
i
p
i
d
s
:
c
o
m
m
o
n
m
e
c
h
a
n
i
s
m
s
i
n
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
sadhesion of Helicobacter pylori to gastrointestinal
cells. Biochemistry 45, 10957-10962
55 Chakrabandhu, K. et al. (2008) The extracellular
glycosphingolipid-binding motif of Fas defines its
internalization route, mode and outcome of signals
upon activation by ligand. Cell Death and
Differentiation 15, 1824-1837
56 Taieb, N. et al. (2009) The first extracellular domain
of the tumour stem cell marker CD133 contains an
antigenic ganglioside-binding motif. Cancer
Letters 278, 164-173
57 Hamel, S., Fantini, J. and Schweisguth, F. (2010)
Notch ligand activity is modulated by
glycosphingolipid membrane composition in
Drosophila melanogaster. Journal of Cell Biology
188, 581-594
58 Snook, C.F., Jones, J.A. and Hannun, Y.A. (2006)
Sphingolipid-binding proteins. Biochimica et
Biophysica Acta 1761, 927-946
59 Kakio, A. et al. (2003) Formation of a membrane-
active form of amyloid β-protein in raft-like model
membranes.BiochemicalandBiophysicalResearch
Communications 303, 514-518
60 Matsuzaki, K. (2007) Physicochemical interactions
of amyloid beta-peptide with lipid bilayers.
Biochimica et Biophysica Acta 1768, 1935-1942
61 Kakio, A. et al. (2002) Interactions of amyloid beta-
protein with various gangliosides in raft-like
membranes: importance of GM1 ganglioside-
bound form as an endogenous seed for Alzheimer
amyloid. Biochemistry 41, 7385-7390
62 Okada, T. et al. (2007) Formation of toxic fibrils of
Alzheimer’s amyloid β-protein-(1-40) by
monosialoganglioside GM1, a neuronal membrane
component. Journal of Molecular Biology 371,
481-489
63 Matsuzaki, K., Kato, K. and Yanagisawa, K. (2010)
Abeta polymerization through interaction with
membrane gangliosides. Biochimica et Biophysica
Acta 1801, 868-877
64 Fantini, J. (2007) Interaction of proteins with lipid
rafts through glycolipid-binding domains:
biochemical background and potential therapeutic
applications. Current Medicinal Chemistry 14,
2911-2917
65 McLaurin, J.A. et al. (1998) Structural transitions
associated with the interaction of Alzheimer β-
amyloid peptides with gangliosides. Journal of
Biological Chemistry 273, 4506-4515
66 Choo-Smith, L.P. and Surewicz, W.K. (1997) The
interaction between Alzheimer amyloid beta(1-40)
peptide and ganglioside GM1-containing
membranes. FEBS Letters 402, 95-98
67 Okada, T. et al. (2008) Formation of toxic
Abeta(1-40) fibrils on GM1 ganglioside-containing
membranes mimicking lipid rafts: polymorphisms
in Abeta(1-40) fibrils. Journal of Molecular Biology
382, 1066-1074
68 Mascioni, A. et al. (2003) High-resolution structure
and localization of amylin nucleation site in
detergent micelles. Biopolymers 69, 29-41
69 Zakharov, S.D. et al. (2007) Helical alpha-synuclein
forms highly conductive ion channels.
Biochemistry 46, 14369-14379
70 Ruf, R.A.S. et al. (2008) alpha-synuclein
conformation affects its tyrosine-dependent
oxidative aggregation. Biochemistry 47,
13604-13609
71 Bosco, D.A. et al. (2006) Elevated levels of oxidized
cholesterol metabolites in Lewy bdy disease brains
accelerate alpha-synuclein fibrilization. Nature
Chemical Biology 2, 249-253
72 Knaus, K.J. et al. (2001) Crystal structure of the
human prion protein reveals a mechanism for
oligomerization. Nature Structural Biology 8,
770-774
73 Krishnan,S.etal.(2003)Oxidativedimerformation
is the critical rate-limiting step for Parkinson’s
disease alpha-synuclein fibrillogenesis.
Biochemistry 42, 829-837
74 Wille, H. et al. (2002) Structural studies of the
scrapie prion protein by electron crystallography.
ProceedingsoftheNationalAcademyofSciencesof
the United States of America 99, 3563-3568
75 Kallberg,Y.etal.(2002)Predictionofamyloidfibril-
forming proteins. Journal of Biological Chemistry
276, 12945-12950
76 Sarnataro,D.etal.(2004)PrPcassociationwithlipid
rafts in the early secretory pathway stabilizes its
cellular conformation. Molecular and Cellular
Biology 15, 4031-4042
77 Naslavski, N. et al. (1999) Sphingolipid depletion
increases formation of the scrapie prion protein in
neuroblastomacellsinfectedwithprions.Journalof
Biological Chemistry 274, 20763-20771
78 Baier, C.J. and Barrantes, F.J. (2007) Sphingolipids
are necessary for nicotinic acetylcholine receptor
export in the early secretory pathway. Journal of
Neurochemistry 101, 1072-1084
79 Gazit,E.(2002)Apossibleroleforpi-stackinginthe
self-assembly of amyloid fibrils. FASEB Journal 16,
77-83
80 Mao, Y. et al. (2010) Surface-induced phase
separation of a sphingomyelin/cholesterol/
ganglioside GM1-planar bilayer on mica surfaces
and microdomain molecular conformation that
expert reviews
http://www.expertreviews.org/ in molecular medicine
18
Accession information: doi:10.1017/S1462399410001602; Vol. 12; e27; September 2010
©Cambridge University Press 2010. Re-use permitted under a Creative Commons Licence – by-nc-sa.
M
o
l
e
c
u
l
a
r
i
n
s
i
g
h
t
s
i
n
t
o
a
m
y
l
o
i
d
r
e
g
u
l
a
t
i
o
n
b
y
m
e
m
b
r
a
n
e
c
h
o
l
e
s
t
e
r
o
l
a
n
d
s
p
h
i
n
g
o
l
i
p
i
d
s
:
c
o
m
m
o
n
m
e
c
h
a
n
i
s
m
s
i
n
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
saccelerates Abeta oligomerization. Biochimica et
Biophysica Acta 1798, 1090-1099
81 Utsumi, M. et al. (2009) Up-and-down topological
mode of amyloid beta-peptide lying on
hydrophilic/hydrophobic interface of ganglioside
clusters. Glycoconjugate Journal 26, 999-1006
82 Ikeda, K. and Matsuzaki, K. (2008) Driving force of
amyloid-β protein to lipid bilayers. Biochemical
and Biophysical Research Communications 370,
525-529
83 Williamson, M.P. et al. (2006) Binding of beta-
peptide to ganglioside micelles is dependent on
histidine-13. Biochemical Journal 397, 483-490
84 Zhao,H.,Tuominen,E.K.andKinnunen,P.K.(2004)
Formation of amyloid fibers triggered by
phosphatidylserine-containing membranes.
Biochemistry 43, 10302-10307
85 Martins, I.J. et al. (2009) Cholesterol metabolism
and transport in the pathogenesis of Alzheimer’s
disease. Journal of Neurochemistry 111,
1275-1308
86 Hu, G. et al. (2008) Total cholesterol and the risk of
Parkinson disease. Neurology 70, 1972-1979
87 Liu, J.P. et al. (2010) Cholesterol involvement
in the pathogenesis of neurodegenerative
disease. Molecular and Cellular Neuroscience 43,
33-42
88 Yanagisawa, K. (2005) Cholesterol and amyloid β
fibrillogenesis. Subcellular Biochemistry 38,
179-202
89 Beel,A.J.etal.(2010)Directbindingofcholesterolto
the amyloid precursor protein: an important
interaction in lipid-Alzheimer’s disease
relationships? Biochimica et Biophysica Acta 1801,
975-982
90 Lahdo, R. and de La Fournière-Bessueille, L. (2004)
Insertion of the amyloid precursor protein
into lipid monolayers: effects of cholesterol and
apolipoprotein E. Biochemical Journal 382,
987-994
91 Harris, J.R. (2008) Cholesterol binding to amyloid
fibrils: a TEM study. Micron 39, 1192-1196
92 Harris, J.R. (2002) In vitro fibrillogenesis of the
amyloid β1-42 peptide; cholesterol potentiation
and aspirin inhibition. Micron 33, 609-626
93 Arispe, N. and Doh, M. (2002) Plasma membrane
cholesterol controls the cytotoxicity of Alzheimer’s
disease AβP( 1 – 40) and (1– 42) peptides. FASEB
Journal 16, 1526-1536
94 Yip, C.M. et al. (2001) Cholesterol, a modulator of
membrane-associated Aβ-fibrillogenesis and
neurotoxicity. Journal of Molecular Biology 311,
723-734
95 Hartmann, T. et al. (2007) Alzheimer’s disease: the
lipid connection. Journal of Neurochemistry 103,
159-170
96 Bar-On, P. et al. (2006) Effects of cholesterol-
lowering compound methyl-beta-cyclodextrin in
models of alpha-synuclein. Journal of
Neurochemistry 98, 1032-1045
97 Bar-On, P. et al. (2008) Statins reduce neuronal
alpha-synuclein aggregation in in vitro models of
Parkinson’s disease. Journal of Neurochemistry
105, 1656-1667
98 Koob, A.O. et al. (2010) Lovastatin ameliorates
alpha-synuclein accumulation and oxidation in
transgenic mouse models of alpha-
synucleinopathies. Experimental Neurology 221,
267-274
99 Mahfoud, R. et al. (2002) A novel soluble analog of
the HIV-1 fusion cofactor, globotriaosylceramide
(Gb(3)), eliminates the cholesterol requirement for
high affinity gp120/Gb(3) interaction. Journal of
Lipid Research 43, 1670-1679
100 Devanathan, S. et al. (2006) Effects of
sphingomyelin, cholesterol and zinc ions on the
binding, insertion and aggregation of the amyloid
Abeta(1-40) peptide in solid-supported lipid
bilayers. FEBS Journal 273, 1389-1402
101 Tsigelny, I.F. et al. (2007) Dynamics of alpha-
synuclein aggregation and inhibition of pore-like
oligomer development by beta-synuclein. FEBS
Journal 274, 1862-1877
102 Stroud, R.M. et al. (1998) Ion-channel-forming
colicins. Current Opinion in Structural Biology 8,
525-533
103 Lashuel, H.A. and Lansbury, P.T., Jr (2006) Are
amyloiddiseasescausedbyproteinaggregatesthat
mimic bacterial pore-forming toxins. Quarterly
Reviews of Biophysics 39, 167-201
104 Palmer, M. (2004) Cholesterol and the activity of
bacterial toxins. FEMS Microbiology Letters 238,
281-289
105 Cherezov, V. et al. (2008) High-resolution crystal
structure of an engineered human beta2-
adrenergicGprotein-coupledreceptor.Science318,
1258-1265
106 Cho, W.J., Trikha, S. and Jeremic, A.M. (2009)
Cholesterol regulates assembly of human islet
amyloid polypeptide on model membranes.
Journal of Molecular Biology 393, 765-775
107 Kayed, R. et al. (2004) Permeabilization of lipid
bilayers is a common conformation-dependent
activity of soluble amyloid oligomers in protein
misfolding diseases. Journal of Biological
Chemistry 279, 46363-4636
expert reviews
http://www.expertreviews.org/ in molecular medicine
19
Accession information: doi:10.1017/S1462399410001602; Vol. 12; e27; September 2010
©Cambridge University Press 2010. Re-use permitted under a Creative Commons Licence – by-nc-sa.
M
o
l
e
c
u
l
a
r
i
n
s
i
g
h
t
s
i
n
t
o
a
m
y
l
o
i
d
r
e
g
u
l
a
t
i
o
n
b
y
m
e
m
b
r
a
n
e
c
h
o
l
e
s
t
e
r
o
l
a
n
d
s
p
h
i
n
g
o
l
i
p
i
d
s
:
c
o
m
m
o
n
m
e
c
h
a
n
i
s
m
s
i
n
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
s108 Mocchetti, I. (2005) Exogenous gangliosides,
neuronal plasticity and repair, and the
neurotrophins. Cellular and Molecular Life
Sciences 19-20, 2283-2294
109 Thomas, P.D. and Brewer, G.J. (1990) Gangliosides
and synaptic transmission. Biochimica et
Biophysica Acta 1031, 277-289
110 Posse de Chaves, E. and Sipione, S. (2010)
Sphingolipids and gangliosides of the nervous
system in membrane function and dysfunction.
FEBS Letters 584, 1748-1759
111 Wakabayashi, M. and Matsuzaki, K. (2007)
Formation of amyloids by Abeta-(1-42) on NGF-
differentiated PC12 cells: roles of gangliosides and
cholesterol. Journal of Molecular Biology 371,
924-933
112 Svennerholm, L. et al. (1994) Membrane lipids of
adulthumanbrain:lipidcompositionoffrontaland
temporal lobe in subjects of age 20 to 100 years.
Journal of Neurochemistry 63, 1802-1811
113 Yu, R.K., Nakatani, Y. and Yanagisawa, M. (2009)
The role of glycosphingolipid metabolism in the
developing brain. Journal of Lipid Research 50,
S440-S445
114 Sohn, H. et al. (2006) Ganglioside GM3 is involved
inneuronalcelldeath.FASEBJournal20,E525-E535
115 Simpson, M.A. et al. (2004) Infantile-onset
symptomatic epilepsy syndrome caused by
homozygous loss-of-fucntion mutation of GM3
synthase. Nature Genetics 36, 1225-1229
116 Svennerholm, L. and Gottfries, C.G. (1994)
Membrane lipids, selectively diminished in
Alzheimer brains, suggest synapse loss as a
primary event in early-onset form (type I) and
demyelination in late-onset form (type II). Journal
of Neurochemistry 62, 1039-1047
117 Grimm, M.O. et al. (2005) Regulation of cholesterol
and sphingomyelin metabolism by amyloid-beta
and presenilin. Nature Cell Biology 7, 1118-1123
118 Bandaru, V.V.R. et al. (2007) ApoE4 disrupts sterol
and sphingolipid metabolism in Alzheimer’s but
not normal brain. Neurobiology of Aging 30,
591-599
119 Ariga, T., McDonald, M.P. and Yu, R.K. (2008) Role
of ganglioside metabolism in the pathogenesis of
Alzheimer’s disease–a review. Journal of Lipid
Research 49, 1157-1175
120 He, X. et al. (2008) Deregulation of sphingolipid
metabolism in Alzheimer’s disease. Neurobiology
of Aging 31, 398-408
121 Xu, Q. and Huang, Y. (2006) Lipid metabolism in
Alzheimer’s and Parkinson’s disease. Future
Lipidology 1, 441-453
122 Chauhan, N.B. (2003) Membrane dynamics,
cholesterol homeostasis, and Alzheimer’s disease.
Journal of Lipid Research 44, 2019-2029
123 Kandiah, N. and Feldman, H.H. (2009)
Therapeutic potential of statins in Alzheimer’s
disease. Journal of the Neurological Sciences 283,
230-324
124 Rea, T.D. et al. (2005) Statin use and the risk of
incident dementia: the Cardiovascular Health
Study. Archives of Neurology 62, 1047-1051
125 Kracun, I. et al. (1992) Cortical distribution of
gangliosides in Alzheimer’s disease.
Neurochemistry International 20, 433-438
126 Barrier, L. et al. (2007) Genotype-related changes of
ganglioside composition in brain regions of
transgenic mouse models of Alzheimer’s disease.
Neurobiology of Aging 28, 1863-1872
127 Molander-Melin, M. et al. (2005) Structural
membranealterationsinAlzheimerbrainsfoundto
be associated with regional disease development:
increased density of gangliosides GM1 and GM2
and loss of cholesterol in detergent-resistant
membrane microdomains. Journal of
Neurochemistry 92, 171-182
128 Barrier, L. et al. (2008) Gender-dependent
accumulation of ceramides in the cerebral cortex of
the APP(SL)/PS1Ki mouse model of Alzheimer’s
disease. Neurobiology of Aging Nov 24; [Epub
ahead of print]
129 Fratiglioni, L. et al. (2000) Incidence of dementia
and major subtypes in Europe: a collaborative
study of population-based cohorts. Neurologic
diseases in the ederly research group. Neurology 5,
S10-S15
130 Butterfield, S.M. and Lashuel, H.A. (2010)
Amyloidogenic protein–membrane interactions:
mechanistic insights from model systems.
Angewandte Chemie. Jul 12; [Epub ahead of print]
131 Iversen,L.L.etal.(1995)Thetoxicityinvitroofbeta-
amyloid protein. Biochemical Journal 311, 1-16
132 Persaud-Sawin, D.A. et al. (2004) A
galactosylceramide binding domain is involved in
traffickingofCLN3fromGolgitoraftsviarecycling
endosomes. Pediatric Research 56, 449-463
133 Zhong, N. et al. (1998) Molecular screening of
Batten disease: identification of a missense
mutation (E295 K) in the CLN3 gene. Human
Genetics 102, 57-62
134 Diaz,J.C.etal.(2009)Smallmoleculeblockersofthe
Alzheimer Abeta calcium channel potently protect
neuronsfromAbetacytotoxicity.Proceedingsofthe
National Academy of Sciences of the United States
of America 106, 3348-3353
expert reviews
http://www.expertreviews.org/ in molecular medicine
20
Accession information: doi:10.1017/S1462399410001602; Vol. 12; e27; September 2010
©Cambridge University Press 2010. Re-use permitted under a Creative Commons Licence – by-nc-sa.
M
o
l
e
c
u
l
a
r
i
n
s
i
g
h
t
s
i
n
t
o
a
m
y
l
o
i
d
r
e
g
u
l
a
t
i
o
n
b
y
m
e
m
b
r
a
n
e
c
h
o
l
e
s
t
e
r
o
l
a
n
d
s
p
h
i
n
g
o
l
i
p
i
d
s
:
c
o
m
m
o
n
m
e
c
h
a
n
i
s
m
s
i
n
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
s135 Panza, F. et al. (2009) Beyond the neurotransmitter-
focused approach in treating Alzheimer’s disease:
drugs targeting beta-amyloid and tau protein.
Aging Clinical and Experimental Research 21,
386-406
136 Waschuk, S.A. et al. (2001) Cellular membrane
composition defines Aβ-lipid interactions. Journal
of Biological Chemistry 276, 33561-33568
137 Thakur, G., Micic, M. and Leblanc, R.M. (2009)
Surface chemistry of Alzheimer’s disease: a
Langmuir monolayer approach. Colloids and
Surfaces B: Biointerfaces 74, 436-456
138 Furukawa, K. et al. (2006) Plasma membrane ion
permeability induced by mutant alpha-synuclein
contributes to the degeneration of neural cells.
Journal of Neurochemistry 97, 1071-1077
139 Oikawa,N.etal.(2009)Gangliosidesdeterminethe
amyloid pathology of Alzheimer’s disease.
Neuroreport 20, 1043-1046
140 Georgieva, E.R. et al. (2008) Membrane-bound
alpha-synuclein forms an extended helix:
long-distance pulsed ESR measurements using
vesicles, bicelles, and rodlike micelles. Journal
of American Chemical Association 130,
12856-12857
141 Jao,C.C.etal.(2008)Structureofmembrane-bound
alpha-synuclein from site-directed spin labeling
and computational refinement. Proceedings of the
National Academy of Sciences of the United States
of America 105, 19666-19671
142 Ulmer, T.S. et al. (2005) Structure and dynamics of
micelle-bound human alpha-synuclein. Journal of
Biological Chemistry 280, 9595-9603
143 Chen, Y., Qin, J. and Chen, Z.W. (2008)
Fluorescence-topographic NSOM directly
visualizespeak-valleypolaritiesofGM1/GM3rafts
in cell membrane fluctuations. Journal of Lipid
Research 49, 2268-2275
144 Zappia, M. et al. (2002) Anti-GM1 ganglioside
antibodiesinParkinson’sdisease.ActaNeurologica
Scandinavia 106, 54-57
145 Sautter,J.etal.(2000)SystemictreatmentwithGM1
ganglioside improves survival and function of
cryopreservedembryonicmidbraingraftedtothe6-
hydroxydopamine-lesioned rat striatum.
Experimental Neurology 164, 121-129
146 Tamboli, I.Y. et al. (2005) Inhibition of
glycosphingolipid biosynthesis reduces secretion
of the β-amyloid precursor protein and amyloid β-
peptide. Journal of Biological Chemistry 280,
28110-28117
147 Malchiodi-Albedi, F. et al. (2010) Lipid raft
disruption protects mature neurons against
amyloid oligomer toxicity. Biochimica et
Biophysica Acta 1802, 406-415
148 Bodner, C.R. et al. (2010) Differential phospholipid
binding of alpha-synuclein variants implicated in
Parkinson’s disease revealed by solution NMR
spectroscopy. Biochemistry 49, 862-871
149 Uversky, V.N. (2007) Neuropathology,
biochemistry, and biophysics of alpha-synuclein
aggregation. Journal of Neurochemistry 103, 17-37
150 Coles, M.et al. (1998) Solution structureof amyloid
beta-peptide(1-40) in a water-micelle environment.
Isthe membrane-spanningdomainwherewethink
it is? Biochemistry 37, 11064-11077
Further reading, resources and contacts
Publications
Butterfield, S.M. and Lashuel, H.A. (2010) Amyloidogenic protein–membrane interactions: mechanistic insights
from model systems. Angewandte Chemie. Jul 12; [Epub ahead of print].
This is avery complete and up-to-date review of the available data on the interaction of amyloidogenic proteins
with model membranes.
Matsuzaki, K., Kato, K. and Yanagisawa, K. (2010) Abeta polymerization through interaction with membrane
gangliosides. Biochimica et Biophysica Acta 1801, 868-877
This excellent review explores the possibility that ganglioside binding is the initial and common step in the
development of human diseases involving amyloidogenic proteins, including Alzheimer disease.
Websites
For a discussion on glycosphingolipid structure and conformation, see our GalCer website:
http://www.galcer.u-3mrs.fr/
(continued on next page)
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sFurther reading, resources and contacts (continued)
The AlzheimerResearch Forumis avery informativefreewebsitededicatedtounderstanding Alzheimerdisease
and related disorders, with resources on amyloidogenic proteins and mutations, and research news:
http://www.alzforum.org/
Useful resources on amyloid pores can be found at the following web page, held by Peter T. Lansbury, Jr:
http://lansbury.bwh.harvard.edu/amyloid_pore.htm
Features associated with this article
Figures
Figure 1. Different pathways of amyloidogenic protein oligomerisation and fibrillation on membrane surfaces.
Figure 2. Neuronal membranes as concentration platforms and chaperones for amyloidogenic monomers: key
role of sphingolipid–cholesterol domains.
Figure 3. Glycosphingolipids and amyloidogenic proteins: a common mechanism of interaction?
Figure 4. A common sphingolipid-binding domain in amyloidogenic proteins.
Figure 5. How glycosphingolipids could promote α-helix structures in amyloidogenic proteins.
Figure 6. Lipid-dependent formation of an α-synuclein oligomeric channel.
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